Chief Marketing Officer

Prior to joining Neurochase in 2025, Jacquie was a member of the ClearPoint Neuro leadership team, where she spearheaded the global initiative that led to the first EU and FDA approvals of the first and only combination gene therapy and drug delivery device for direct intraparenchymal delivery to the brain, bypassing the blood-brain barrier.

Prior to this, Jacquie she spent over 15 years helping novel medical device technologies in interventional cardiology and oncology cross the adoption chasm in multiple geographies at major multi-national companies including Philips and Volcano Corporation.